SAGE Therapeutics Inc at Stifel CNS Day Transcript
Great. Good morning, everybody, and thanks for joining our Third Annual Neuroscience Conference. Definitely great to be starting it off with Barry. It's the first discussion. I think we're doing on camera since you joined Sage, maybe we did one at a conference in the fall, but more -- so no online questions today on Sage. But thank you, man. And maybe you want to kick it off and just sort of set the stage with the update in zuranolone trials, tremor and NMDA, and then we can get into specifics, Barry. That sounds good?
Yes. Yes. Thanks, Paul. And I appreciate Stifel for having us. And it's wonderful to kick off your third annual and be the lead company. So yes, things are going incredibly well. I'm excited by the progress we're making at Sage. As I've said before, we're positioned to be a top-tier biopharmaceutical company and the leader in brain
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |